acetonaphthoneimine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: acetonaphthoneimine
• 英文别名: 1-Naphthalen-1-yl-ethylideneamine；1-naphthalen-1-ylethanimine
• 化学式: C₁₂H₁₁N
• 分子量: 169.226
• InChiKey: KMMGAUINEULPQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  23.8
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  acetonaphthoneimine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 1-(萘-1-基)乙胺盐酸盐
  参考文献：
  名称：

  合成具有布替萘芬结构元件构象固定的潜在角鲨烯环氧化酶抑制剂

  摘要：

  报道了萘甲胺 6b-h 的合成，其中将空间要求增加的取代基引入 α 位置以进行构象固定。由于萘基烷酮 3 与胺 9 和 10 的还原胺化现在可以在非常有限的范围内使用，因此首先以各种方式合成 α-取代萘甲胺 2 和 4 作为合适的中间体，然后才合成所需的 N 取代模式目标化合物通过合适的 - 主要是还原 - 烷基化方法建立。

  DOI：

  10.1002/ardp.19933260607
• 作为产物：
  描述：

  1-(1-azidoethyl)naphthalene 在 ([2,5-Me2-3,4-Ph2(η5-C4CNHPh)]Ru(CO)(μ-CO))2 作用下， 以 四氢呋喃 为溶剂， 生成 acetonaphthoneimine
  参考文献：
  名称：

  C–H Activation Guided by Aromatic N–H Ketimines: Synthesis of Functionalized Isoquinolines Using Benzyl Azides and Alkynes

  摘要：

  Aromatic N-H ketimines were in situ generated from various benzylic azides by ruthenium catalysis for the subsequent Rh-catalyzed annulation reaction with alkynes to give the corresponding isoquinolines. In contrast to conventional synthetic methods for aromatic NH ketimines, our protocol works under mild and neutral conditions, which enabled the synthesis of isoquinolines having various functionalities such as carbonyl, ester, alkenyl, and ether groups. In addition, the imidates generated from alpha-azido ethers were successfully used for the synthesis of 1-alkoxyisoquinolines.

  DOI：

  10.1021/jo501465q

文献信息

• Generation of Organozinc Reagents by Nickel Diazadiene Complex Catalyzed Zinc Insertion into Aryl Sulfonates
  作者：Philippe Klein、Vivien Denise Lechner、Tanja Schimmel、Lukas Hintermann

  DOI：10.1002/chem.201904545

  日期：2020.1.2

  ArX electrophiles has typically been restricted to iodides and bromides. The insertions of zinc dust into the C-O bonds of various aryl sulfonates (tosylates, mesylates, triflates, sulfamates), or into the C-X bonds of other moderate electrophiles (X=Cl, SMe) are catalyzed by a simple NiCl2 -1,4-diazadiene catalyst system, in which 1,4-diazadiene (DAD) stands for diacetyl diimines, phenanthroline, bipyridine

  通过将锌直接插入ArX亲电试剂的CX键中来生成芳基锌试剂（ArZnX）通常仅限于碘化物和溴化物。锌粉插入各种芳基磺酸盐（甲苯磺酸盐，甲磺酸盐，三氟甲磺酸盐，磺酸盐）的CO键中，或插入其他中等亲电试剂（X = Cl，SMe）的CX键中均通过简单的NiCl2 -1,4-催化二氮杂二烯催化剂体系，其中1,4-二氮杂二烯（DAD）代表二乙酰基二亚胺，菲咯啉，联吡啶和相关配体。现在，在室温下在DMF或N​​MP溶液中进行催化锌化可提供芳基锌磺酸盐，这些芳基锌磺酸盐会经历典型的催化交叉偶联或亲电取代反应。
• COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS
  申请人：Research Triangle Institute

  公开号：EP2788359B1

  公开（公告）日：2017-03-01
• [EN] ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS<br/>[FR] INHIBITEURS OXIMYLE ACYCLIQUES DE PROTÉASE DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2007146695A1

  公开（公告）日：2007-12-21

  [EN] The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
  [FR] La présente invention concerne des composés répondant à la formule I ou des sels, des esters, ou des promédicaments pharmaceutiquement acceptables de ces composés, qui inhibent l'activité de la sérine protéase, en particulier l'activité de la protéase NS3-NS4A du virus de l'hépatite C (VHC). En conséquence, les composés de la présente invention interfèrent avec le cycle de vie du virus de l'hépatite C et ils se révèlent également utiles en tant qu'agents antiviraux. La présente invention concerne en outre des compositions pharmaceutiques contenant les composés susmentionnés, destinés à être administrés à un sujet souffrant d'une infection par le VHC. L'invention concerne également des procédés de traitement d'un sujet atteint d'une infection par le VHC par l'administration d'une composition pharmaceutique contenant les composés de la présente invention.
• [EN] OXIMYL HCV SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS OXIMYLES DE LA SÉRINE PROTÉASE DE VHC
  申请人：ENANTA PHARM INC

  公开号：WO2009076166A2

  公开（公告）日：2009-06-18

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• [EN] FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS<br/>[FR] COMPOSÉS À BASE DE TRIPEPTIDES FLUORÉS INHIBANT LA SÉRINE PROTÉASE DU VHC
  申请人：ENANTA PHARM INC

  公开号：WO2009076173A2

  公开（公告）日：2009-06-18

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ( I ) which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.